EllisLevineMD

PubMed

• 107 citations
  The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort
  Foluso O. Ademuyiwa, Austin Miller, Tracey O'Connor, Stephen B. Edge, Mangesh A. Thorat
  Breast Cancer Research and Treatment. 2011-01-01
• 47 citations
  Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma
  Venkata K. Pokuri, Johar R. Syed, Zhengyu Yang, Erinn Field, Susanna Cyriac
  Clinical Genitourinary Cancer. 2014-05-20
• 22 citations
  Efficacy of Palbociclib Combinations in Hormone Receptor–Positive Metastatic Breast Cancer Patients After Prior Everolimus Treatment
  Ajay Dhakal, Christina Matthews, Ellis G. Levine, Kilian E. Salerno, Fan Zhang
  Clinical Breast Cancer. 2018-04-28

Journal Articles

• Kidney cancer, version 22014  
  Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolgr GB, Chang SS, Choueriri TK, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, L..., J Natl Compr Canc Netw, 1/1/2014
• A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma  
  Hussain M, Daignault S, Agarwal N, Grivas PD, Siefker-Radke AO, Puzanov I, MacVicar GR, Levine EG, Srivivas S, Twardowski P, Eisenberger MA, Quinn DI, Vaishampayan UN,..., Cancer, 1/1/2014
• Exercise intervention in breast cancer patients with aromatase inhibitor-associated arthralgia: a pilot study  
  Denysschen CA, Burton H, Ademuyiwa F, Levine E, Tetewsky S, O’Connor T, Eur J Cancer Care, 1/1/2014
• Understanding avoidance, refusal and abandonment of chemotherapy before and after cystectomy for bladder cancer  
  Rehman S, Crane A, Stegemann AP, Din R, Shi Y, Wilding G, Levine EG, George S, Trump DL, Guru KA, Urology, 1/1/2013
• Time-trends in survival in young women with breast cancer in a SEER population-based study  
  Ademuyiwa FO, Groman A, Hong CC, Miller A, Kumar S, Levine E, Erwin D, Ambrosome C, Breast Cancer Res Treat, 1/1/2013
• Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis  
  Ngamphaiboon N, O’Connor TL, Advani PP, Levine EG, Kossoff EB, Med Oncol, 1/1/2012
• The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort  
  Ademuyiwa FO, Miller A, O’Connor T, Edge SB, Thorat MA, Sledge GW, Levine E, Badve S, Breast Cancer Res Treat, 1/1/2011
• Phase II trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration resistant prostate cancer  
  Chadha MK, Tian L, Mashtare T, Payne V, Silliman C, Levine E, Wong M, Johnson C, Trump D, Cancer, 1/1/2010
• NCCN clinical practice guidelines in oncology: testicular cancer  
  Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Chhoueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR Jonasch E, Kessinger A, Kuzel TM, Lange PH, L..., J Natl Compr Canc Netw, 1/1/2009
• Length of survival in Hospice for cancer patients referred from a comprehensive cancer center  
  Younis T, Milch R, Abul-Khoudoud N, Lawrence D, Mirand A, Levine E, Am J Hospice and Palliative Medicine, 1/1/2009
• A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer  
  O’Connor T, Rustum Y, Levine E, Creaven P, Cancer Chemotherapy and Pharmacology, 1/1/2008
• What did you think of the hematology/oncology rotation? A survey of Internal Medicine Residents  
  Chen H, Mortazavi A, Levine E, Kamisetti S, Kamisetti S, Ramnath N, Journal of Cancer Education, 1/1/2007
• Kidney cancer Clinical practice guidelines in oncology  
  Motzer RJ, Bolger GB, Boston B, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Jonasch E, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margollin KA..., J Natl Compr Canc Netw, 1/1/2006
• HER-2/neu evaluation in breast cancer Pathology Patterns Reviews  
  Winston JS, Ramanarayan J, Levine EG, Am J Clin Pathol, 1/1/2004
• Barriers to clinical trial participation by older women with breast cancer  
  Kemeny MM, Peterson B, Kornblith AB, Muss HB, Wheeler J, Levine E, Bartlett N, Fleming G, Cohen HJ, J Clin Oncol, 1/1/2003
• Thiophilic interaction chromatography facilitates detection of various molecular complexes of prostate-specific antigen in biological fluids  
  Kawinski E, Levine E, Chadha K, The Prostate, 1/1/2002
• Is MUGA scan necessary in low-risk breast cancer patients prior to doxorubicin-based adjuvant therapy  
  Sabel MS, Levine EG, Hurd T, Schwartz GN, Zielinski R, Hohn D, Edge SB, Am J Clin Oncol, 1/1/2001
• Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer  
  Kaufman D, Raghavan D, Carducci M, Levine EG, Murphy B, Aisner J, Kuzel T, Nicol S, Stadler W, J Clin Oncol, 1/1/2000
• Phase II trial of topotecan in advanced breast cancer: A Cancer and Leukemia Group B Study  
  Levine E, Cirrincione CT, Szatrowski TP, Canellos G, Norton L, Henderson, IC, American Journal of Clinical Oncology, 1/1/1999
• Flow cytometric DNA analysis of invasive carcinomas detected by screening mammography: Use of specimen mammography-guided fine needle aspirates  
  Stomper, PC, DeBloom JR, Levine E, Budnick RM, Stewart CC, Clinical Cancer Research, 1/1/1998
• Unusual central nervous system toxicity in a phase I study of N1N11Diethylnorspermine in patients with advanced malignancy  
  Creaven PJ, Perez R, Pendyala L, Meropol N, Loewen G, Levine E, Berghorn E, Raghavan D, Invest New Drugs, 1/1/1997
• Therapy for inflammatory breast cancer: Impact of doxorubicin-based therapy  
  Bauer, RL. Busch E,. Levine E, Edge SB, Annals of Surgical Oncology, 1/1/1995
• Phase I and pharmacokinetic evaluation of floxuridine/leucovorin given on the Roswell Park weekly regimen  
  Creaven PJ, Rustum YM, Petrelli NJ, Meropol NJ, Raghavan D, Rodriguez-Bigas M, Levine EG, Frank C, Udvary-Nagy S, Proefrock A, Cancer Chemother Pharmacol, 1/1/1994
• MVAC for bladder cancer: Time to move forward again  
  Levine E, Raghavan D, Journal of Clinical Oncology, 1/1/1993
• Book review of Testicular Cancer: Investigation and Management  
  Levine EG, Journal of the National Cancer Institute, 1/1/1992
• Join now to see all

Books/Book Chapters

• Textbook of Uncommon Cancer 
  Chapter: Sarcomas of the adult prostate gland 
  Levine, EG, Gaeta JF, Huben RF:Editors: Raghavan D, Brecher M, Johnson DH, Meropol NJ, Thigpen JY.John Wiley & Sons, Ltd., Sussex, England1999
• Principles and Practice of Genitourinary Oncology 
  Chapter: Genitourinary sarcomas 
  Levine EG, Brooks JSJ, Spellman J, Velagapudi SEditors: Raghavan D, Scher HI, Leibel SA, Lange PH.J.B. Lippincott Company, Philadelphia, PA1997
• Cancer Patient Follow-up: Surveillance Strategies After Primary Treatment of Cancer 
  Chapter: Breast carcinoma 
  Edge SB, Levine EG, Arredondo MA, Tezcan HEditors: Johnson FE, Virgo KS.Mosby-Year Book, Inc., St. Louis1997
• Medical Oncology 
  Chapter: Leukemias 
  Bloomfield CD, Foon KA, Levine EGEditors: Calabresi P, Schein PS.McGraw Hill, Inc., New York, NY1993
• Neoplastic Diseases of the Blood 
  Chapter: Cytogenetics of malignant lymphoma 
  Levine EG, Bloomfield CDEditors: Wiernik PH, Canellos GP, Kyle RA, Schiffer CA.Churchill Livingstone, New York, NY1991
• Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances 
  Chapter: Banded chromosome abnormalities in non-Hodgkin's lymphoma. Correlations with morphology, immunologic phenotype and clinical course 
  Bloomfield CD, Arthur DC, Levine EG, Frizzera G, Gajl-Peczalska KJ, LeBien TW, Hurd DD, Peterson BAEditors: Cavalli F, Bonadonna G, Rozencweig M.Martinus Nijhoff Publishers, Hingham, MA1985
• Join now to see all

Abstracts/Posters

• Secondary breast cancer following hematologic malignancies
  Tanveer F, Ford LA, Wang ES, Levine EG, O’Connor TL, Wetzler M, Proc Am Soc Clin Oncol, 1/1/2014
• Predictors of complete pathological response (pT0) to neoadjuvant chemotherapy (NAC) in muscle-invasive bladder carcinoma (MIBC)
  Pokuri VK, Syed JR, Yang Z, Field EP, Pili R, Levine EG, Trump DL, Hutson A, Guru K, George S, Proc Am Soc Clin Oncol, 1/1/2014
• Tolerability and cardiac safety of neo/adjuvant trastuzumab-based chemotherapy regimens for HER2+ breast cancer: A single institution experience
  Jitawatanarat P, Kossoff E, Riebandt G, Levine EG, O’Connor TL, Chittawatanarat K, Ngamphaiboon N, Proc Am Soc Clin Oncol, 1/1/2013
• A phase 1b dose-escalation study of TRC105 (anti-endoglin antibody) in combination with capecitabine for advanced solid tumors (including patients with progressive or ...
  Levine EG, Forero A, O’Connor T, Seon BK, Jivani MA, Adams BJ, Theuer CP, Proc Am Soc Clin Oncol, 1/1/2013
• A single-center experience of chemotherapy for muscle-invasive bladder cancer after radical cystectomy
  Kotowski AS, Stegemann A, Rehman S, Attwood K, Levine EG, Guru K, Trump DL, Pili R, J Clin Oncol and ASCO Genitourinary Cancer Symposium, 2/1/2012
• Factors affecting delivery of planned neoadjuvant/adjuvant chemotherapy for breast cancer in older women
  Ngamphaiboon N, Edge SB, Groman A, Kossoff EB, Wilding GE, Ademuyiwa F, Levine EG, Watroba N, O’Connor TL, San Antonio Breast Cancer Symposium, 12/1/2011
• A long journey from target discovery to clinical application: Discovery of endoglin and development of chimeric anti-endoglin antibody for targeting tumor vasculature...
  Seon BK, Haba A, Harada N, Tsujie M, Toi H, Tsai J, Duzen K, Fukita DA, Mendelson LS, Rosen JW, Goldman JW, Gordon MS, Hurwitz H, Wong M, Levine E, Adams BJ, Theuer CP..., 2011 Era of Hope Meeting, 8/1/2011
• Phase II trial of neoadjuvant pegylated liposomal doxorubicin with paclitaxel and trastuzumab in patients with operable Her-2 positive breast cancer
  Hymans DM, Leichman GC, Klein P, Reitchsel P, Levine EG, Gelski VJ. Kelley MA, Cancer Research and San Antonio Breast Cancer Symposium, 12/1/2009
• Length of survival (LOS) of cancer patients in hospice and prior enrollment in phase I studies
  Younis T, Milch R, Abul-Khoudoud N, Lawrence D, Mirand A. Walsh D, and Levine EG, Proc Am Soc Clin Oncol, 1/1/2004
• A model for predicting progression free survival in men with hormone refractory prostate cancer (HRPC): An analysis of CALGB studies
  Halabi S, Small E, Kattan M, Kantoff P, Dawson N, Levine E, Oh W, Kaplan E, Vogelzang N, Proc Am Soc Clin Oncol, 1/1/2003
• A model for predicting survival in men with hormone refractory prostate cancer (HRCaP): An analysis of CALGB studies
  Halabi S, Small EJ, Kantoff PW, Dawson NA, Levine EG, Vogelzang NJ, Proc Am Soc Clin Oncol, 1/1/2002
• Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: Initial results from intergroup trial 0100 (SWOG 8814)
  Albain KS, Green SJ, Ravdin PM, Cobau CD, Levine EG, Ingle JN, Pritchard KI, Schneider DJ, Abeloff MD, Norton L, Henderson IC, Lew D, Livingston RB, Martino S, Osborne CK, Proc Am Soc Clin Oncol, 1/1/2002
• Overall survival after cyclophosphamide, Adriamycin, 5-FU, and tamoxifen (CAFT) is superior to T alone in postmenopausal, receptor (+), node (+) breast cancer: New fi...
  Albain K, Green S, Ravdin P, Cobau C, Levine E, Ingle J, Pritchard K, Schneider D, Abeloff M, Norton L, Lew D, Martino S, Osborne K, Proc Am Soc Clin Oncol, 1/1/2001
• Phase I trial of recombinant human anti-Her2 monoclonal antibody (H) plus low-dose interleukin-2 (IL-2) in patients with solid tumors
  Fleming GF, Meropol NJ, Hollis DR, Rosner GL, Fracasso PM, Sosman JA, Tkaczuk L, Levine EG, Rhoades C, Caligiuri MA, Carson WE, Ratain MJ, Proceedings of the American Society of Clinical Oncology, 1/1/1999
• Preliminary results of CALGB 9680: A phase II trial of high dose mitoxantrone/GM-CSF and low dose steroids in hormone refractory prostate cancer (HRPC)
  Levine EG, Halabi S, Hars V, Rago R, Vogelzang NJ, Proceedings of the American Society of Clinical Oncology, 1/1/1998
• Tamoxifen (T) vs. Cyclophosphamide, Adriamycin, and 5-FU (CAF) pluse either concurrent or sequential T in postmenopausal receptor (+), node (+) breast cancer: A South...
  Albain K, Green S, Osborne K, Cobau C, Levine E, Ingle J, Pritchard K, Schneider D, O'Sullivan J, Hess E, Martino S, Proceedings of the American Society of Clinical Oncology, 1/1/1997
• Practice guidelines in breast cancer: Guideline variations in a comprehensive cancer center
  Edge SB, Watroba N, Arredondo MA, Carson WC, Levine E, Schwartz G, Kim S, Breast Cancer Research and Treatment, 1/1/1996
• A phase II study of gemcitabine in the treatment of patients with advanced transitional cell carcinoma
  Stadler W, Kuzel T, Raghavan D, Levine E, Vogelzang N, Dorr FA, Proceedings of the American Society of Clinical Oncology, 1/1/1995
• Minimum 6 year follow-up of 133 patients (PTS) aged >70 years treated for breast cancer (CAB)
  Villalona-Calero M, Budnick R, Levine E, Walsh D, Stewart C, Penetrante R, Tsangaris T, Raghavan D, Proceedings of the American Society of Clinical Oncology, 1/1/1993
• Phase I clinical trial of floxuridine (FUdR) with leucovorin (LV) in patients (PTS) with advanced genitourinary cancer (AGC)
  Raminski D, Creaven PJ, Rustum YM, Perrapato S, Huben R, Levine E, Berghorn E, Proceedings of the American Society of Clinical Oncology, 1/1/1992
• Cytogenetic heterogeneity of true histiocytic lymphoma
  Dohner H, Frizzera G , Levine E, Griesinger F, Jaszcz W, Peterson BA, Arthur DC, Blood, 1/1/1990
• Autologous transplantation (TXN) in Hodgkin's disease (HD) using bone marrow (BMSC) or peripheral blood (PBSC) derived stem cells
  Hurd D, Lasky L, Haake R, Peterson B, Kim T, Christiansen N, Weisdorf D, Bostrom B, Levine E, McGlave P, Bloomfield C, Proceedings of the American Society of Clinical Oncology, 1/1/1988
• Recurring chromosome translocations in B-cell malignant lymphoma
  Bloomfield CD, Levine EG, Machnicki J, Frizzera G, Gajl-Peczalska KJ, Arthur DC, Ninth International Human Gene Mapping Workshop and Cytogenet Cell Genet, 1/1/1987
• Prognostic significance of cytogenetic abnormalities in non-Hodgkin's lymphoma
  Levine EG, Arthur DC, Frizzera G, Peterson BA, Hurd DD, and Bloomfield CD, Blood, 1/1/1986
• Cytogenetic analysis in lymphomas predicts survival
  Levine EG, Arthur DC, Frizzera G, Peterson BA, Hurd DD, and Bloomfield CD, Education Booklet of the LSA Medical Conference: Second National Symposium, 1/1/1986
• Join now to see all

Lectures

• The Evaluation System has Changed: Introduction to the Milestones 
  Roswell Park Cancer Institute, Buffalo, NY - 8/12/2014
• Managing Treatments’s Side Effects in Advanced Prostate Cancer 
  Buffalo, NY - 8/24/2012
• Breast Cancer - When to Treat and What to Use? 
  Buffalo, NY - 10/16/2010
• Breast Cancer 
  Buffalo, NY - 7/15/2006
• Drugs Commonly Used in Breast Cancer 
  Hyatt Regency, Buffalo, NY - 10/29/2004
• Systemic Issues in Breast Cancer 
  Buffalo, NY - 4/7/2004
• Hot Topics at ASCO 
  Roswell Park Cancer Institute, Buffalo, NY - 6/14/2003
• Adjuvant Chemotherapy and Tamoxifen Treatment: Which Patients Benefit? 
  Buffalo, NY - 3/9/2002
• Update Across the Disciplines on the Prevention and Treatment of Breast Cancer 
  Buffalo, NY - 11/4/2000
• Ethics of Clinical Trials 
  Buffalo, NY - 11/3/1999
• Breast Cancer: Preservation of the Breast 
  Buffalo, NY - 10/29/1998
• Adjuvant Treatment of Localized Breast Cancer-New Approaches 
  Buffalo, NY - 5/14/1998
• Clinical Trials Offered to Women with Breast Cancer at RPCI 
  East Aurora, NY - 5/14/1997
• Principles of solid tumor chemotherapy 
  Buffalo, NY - 12/18/1996
• How to be a study chair 
  Miami Beach, FL - 5/4/1996
• Peripheral primitive neuroectodermal tumors in adults 
  Buffalo, NY - 4/19/1996
• Advanced breast cancer: What have we learned from clinical trials? 
  Buffalo, NY - 10/6/1995
• Residual disease following cytoreductive chemotherapy of testicular cancer 
  Buffalo, NY - 10/14/1994
• Outpatient approaches to cancer medicine 
  Millard Fillmore Hospital, Buffalo, NY - 11/15/1990
• Recent progress in genitourinary malignancies 
  1/17/1990
• Chemotherapeutic approach to testis cancer 
  10/7/1989
• Follicular lymphoma as a paradigm for new treatment approaches in cancer medicine 
  5/4/1989
• Cytogenetic correlates in the non-Hodgkin's lymphomas 
  Buffalo, NY - 2/16/1989
• Follicular lymphomas: Where have we been? Where should we go? 
  Atlanta, GA - 10/27/1988
• Current concepts in the genetics of common cancers 
  2/21/1987
• Join now to see all